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Abstract
Background: The impact of diuretic usage and dosage on the mortality of critically ill patients with acute kidney injury is still
unclear.
Methods and Results: In this prospective, multicenter, observational study, 572 patients with postsurgical acute kidney
injury receiving hemodialysis were recruited and followed daily. Thirty-day postdialysis mortality was analyzed using Cox’s
proportional hazards model with time-dependent covariates. The mean age of the 572 patients was 60.8616.6 years.
Patients with lower serum creatinine (p=0.031) and blood lactate (p=0.033) at ICU admission, lower predialysis urine
output (p=0.001) and PaO2/FiO2 (p=0.039), as well as diabetes (p=0.037) and heart failure (p=0.049) were more likely to
receive diuretics. A total of 280 (49.0%) patients died within 30 days after acute dialysis initiation. The analysis of 30-day
postdialysis mortality by fitting propensity score-adjusted Cox’s proportional hazards models with time-dependent
covariates showed that higher 3-day accumulated diuretic doses after dialysis initiation (HR=1.449, p=0.021) could increase
the hazard rate of death. Moreover, higher time-varying 3-day accumulative diuretic doses were associated with
hypotension (p,0.001) and less intense hemodialysis (p,0.001) during the acute dialysis period.
Background and Significance: Higher time-varying 3-day accumulative diuretic dose predicts mortality in postsurgical
critically ill patients requiring acute dialysis. Higher diuretic doses are associated with hypotension and a lower intensity of
dialysis. Caution should be employed before loop diuretics are administered to postsurgical patients during the acute
dialysis period.
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Introduction
Postoperative acute kidney injury (AKI) is a serious complica-
tion resulting in prolonged hospital stays and high mortality rates
[1]. AKI develops in 5% to 30% of postsurgical patients and is
associated with a mortality rate of 60% to 90% [2,3,4]. Prerenal
azotemia and ischemic acute tubular necrosis (ATN) are the
predominant causes of AKI [5]. During the perioperative period,
fluid balance is one of the most important issues [6]. It is
reasonable to consider that diuretic use could help preserve urine
output and thereby shorten the dialysis period for better fluid
management. Loop diuretics may convert oliguric into nonoliguric
form of AKI, allowing easier fluid and/or nutritional support for
the patient. Furosemide is a loop diuretic and a vasodilator, which
may decrease the metabolic work of the thick ascending limb [7].
Diuretic use in critically ill patients with acute kidney injury is
reported not related to mortality [6]. High-dose furosemide
(35 mg/kg/d orally) was used in patients with AKI requiring
dialysis but did not have an impact on the survival and renal
recovery rates [8]. It was reported diuretic might confer a survival
advantage in patients on hemodialysis [9]. Loop diuretic use after
dialysis in DOPPS study ranged from 9.2% in the United States to
21.3% in Europe, whereas use within 90 days of starting dialysis
therapy ranged from 25.0% in the United States to 47.6% in
Japan [9]. Preoperative diuretic use could be associated with
postoperative AKI [10]; however, the association between
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e30836patients’ mortality and diuretic use in postoperative critical
patients receiving acute dialysis has not been elucidated.
The concern about acute dialysis-related mortality usually
focuses on the severity of the predialytic disease. However,
predialysis risk factors may have different effects on short- and
long-term survival, and the risk factors assessed at initial dialysis
may change over time [11,12]. Thus, in view of the complex
relationship between diuretic use and mortality in critically ill
patients, we used a comprehensive approach with both time-
independent and time-dependent predictor variables to test the
hypothesis that diuretic use during acute dialysis affects mortality
in postsurgical patients.
Results
Patients’ basic demographic characteristics
A total of 572 critically ill patients (191 women; mean age,
60.8616.6 years) who had received acute RRT after major surgical
operations were recruited and followed daily (Figure 1). The mean
APACHE II score was 11.366.0, and SOFA score was 8.363.5 at
ICU admission. Among the patients, 424 (74.1%) used diuretics
during the first three days of initial hemodialysis. The histogram of
initially accumulated 3-day diuretic dose after RRT is shown in
Figure 2. At dialysis initiation, the mean APACHE II and SOFA
scoreswere12.966.3and 11.463.7,respectively.Themeantimeto
dialysis from ICU admission was 6.6618.0 days. Postoperatively,
283 (49.5%) patients died within 30 days after dialysis, which
accounted for 77.3% of hospital mortality. After dialysis, only 193
(33.7%) patients were successfully withdrawn from acute dialysis.
Predialysis assessments
Before dialysis, 417 (72.9%) postsurgical patients received
inotropics treatment, and 94 (16.4%) developed anuria. Most
patients underwent cardiovascular surgery (203, 35.5%). Although
there were multiple indications for starting hemodialysis, oliguria
(51.6%) and fluid overload (15.7%) were the leading causes for
acute hemodialysis. Most (73.6%) of the patients had a status that
was more severe than the injury criteria of the RIFLE classification
upon initial dialysis.
The indications of acute hemodialysis were the same between 3-
day predialysis diuretic and nondiuretic use groups. The SOFA
score was higher at ICU admission in the nondiuretic than the
diuretic group (p=0.006). However, there were no differences in
duration from hospital admission to dialysis, duration from ICU
admission to dialysis, comorbidities, operation types, indication of
acute dialysis or disease severity at the beginning of dialysis
between the two groups (Table 1, 2). Patients with diuretic use had
lower PaO2/FiO2 (p=0.011) before the first hemodialysis session.
At the initiation of dialysis, the survival patients had lower
disease severity scores (APACHE II, SOFA, and SAPA, all
p,0.001), but the ratio of diuretic use was the same between two
groups, (p=0.775) (Table 3,4).
Figure 1. Flow diagram of the study population.
doi:10.1371/journal.pone.0030836.g001
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To explore what types of patients would require diuretics upon
dialysis initiation, we conducted a logistic regression analysis and
established a propensity score model. Variables (Table 1,2) were
included for inclusion in the new propensity score model.
Finally, based on the fitted logistic regression model (see
Table 5), the propensity score for treatment with diuretic upon
initializing acute dialysis was estimated (see File S1).
Factors associated with 30-day postdialysis mortality
The serial measurement of accumulated diuretics through the
spectrum and duration of RRT was significant to predict 30-day
postdialysis mortality (p=0.021) during the dialysis period, using
Cox’s model adjusted with time-varying significant covariates
(Table 6 and Figure 3). Regardless of diuretic use, patients who
died were significantly more likely to have liver failure (p,0.001),
and have a higher ratio of azotemia (p=0.038) when dialysis
began. Older age (p,0.001), higher APACHE II score (p,0.001),
lower daily PaO2/FiO2 (p,0.001), higher daily lactate (p,0.001),
and less daily IHD versus no dialysis (p=0.030) were associated
with 30-day postdialysis mortality (Table 4). The final Cox’s model
fit the observed data well; the adjusted generalized R
2=0.495.
In the sensitivity test, a higher accumulated diuretic dose
predicted mortality in the postsurgical critically ill noncardiac
surgery patients requiring acute dialysis ( p,0.01).
Diuretic dose associated with daily variables
To examine the effect of diuretic use and decrease the residual
confounding factors (e.g., fluid overload, oliguria, and tissue
hypoxia), daily variable factors (body weight, urine output, mean
blood pressure, PaO2/FiO2, lactate, BUN, and creatinine) were
correlated to the time-varying three-day accumulative diuretic
dose, as shown in the GEE model, and plotted by smoothed GAM
plot after adjusting for all the covariates listed in Table 1. Diuretic
use was significantly associated with the intensity of dialysis
(p,0.001) (Table S1) and daily mean blood pressure (p,0.001)
(Table S2 and Figure 4), but not with daily PaO2/FiO2 (p=0.293),
lactate (p=0.948), BUN (p=0.905), body weight (p=0.449),
creatinine (p=0.653), and urine output (p=0.075).
Discussion
Given the high incidence of AKI in the ICU and its high
morbidity, better evidence is needed to guide AKI treatment
strategies. Few studies have demonstrated any material benefit of
diuretic use in AKI apart from augmenting urine output, and
some studies have suggested potential deleterious effects [13,14].
Although two of the previous controlled studies found a trend
toward improvement in renal function recovery rates with diuretic
use [15], one cohort analysis suggested that diuretics may delay
renal recovery [13]. Diuretic use has not been found to shorten the
duration of AKI, reduce the need for dialysis, or improve overall
outcomes [16].
Our study evaluated the relationships between diuretic use and
dose with subsequent mortality after dialysis, unlike the previous
report by Uchino [6], which used distinct multivariate models.
The current study adds to this previous work [13] in that it
identifies a group of patients, who have increased mortality and
not just delayed or diminished return of renal function. Firstly, to
ensure that our results were reliable, we only included postsurgical
AKI patients receiving acute dialysis in surgical ICUs. In our
patient cohort, all patients received dialysis; however, only 70%
patients in Uchino’s study received dialysis. Secondly, to show the
interactions between diuretics and dialysis settings, we recorded
the daily dialysis modality and settings; Uchino recorded only
diuretic use at the time of acute kidney injury or dialysis initiation
[6].
Furosemide is nondialysable, and retained up to 6 to 8 hours in
patients with chronic renal failure; however no specific dosage
adjustment of furosemide is necessary for dialysis patients [17]. It is
effective for the treatment of edema associated with renal failure
[18]. Therefore, diuretic use and dosage is likely to have effects on
patients’ outcomes. In our study, similar to a previous study on
high furosemide doses for established acute renal failure [8], renal
recovery rates did not differ between the diuretic and nondiuretic
Figure 2. Histogram of accumulated 3-day diuretic use before dialysis initiation (equivalent of furosemide, mg).
doi:10.1371/journal.pone.0030836.g002
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recognition of AKI and might delay the timing of dialysis [13],
which might be related to patient mortality. In our study, the
duration between hospital admission to dialysis or ICU admission
to dialysis did not differ among patients who were taking or not
taking diuretics at initial dialysis, and no lead-time bias was found
between the two groups. Our propensity score, lower predialysis
PaO2/FiO2 saturation, reduced urine output, lower creatinine
level, and lower lactate level at admission were predictors of
diuretic use, which reflected the general features of the use of
diuretics in critical care.
Using a time-dependent Cox’s regression model that considers
risk factors changing over time, rather than a traditional Cox’s
model with only fixed baseline risk factors, was an important
analysis strategy, especially in critical patients with changing daily
variables and inconsistent diuretic use [11]. Diuretic use when
Table 2. Comparison of predialysis clinical characteristics of
the nondiuretic and diuretic groups.
Nondiuretic Diuretic p
(n=148) (n=424)
Indication for acute dialysis
Azotemia 48 (32.4%) 117 (27.6%) 0.292
Fluid overload 23 (15.5%) 67 (15.9%) 0.999
Hyperkalemia 11 (7.4%) 32 (7.5%) 0.999
Oliguria 72 (48.6%) 223 (52.6%) 0.445
Acidosis 4 (2.7%) 17 (4.0%) 0.615
At dialysis initiation
1
Hospital admission to dialysis, mean
(SD), days
18.1 (36.7) 17.7 (35.5) 0.913
ICU admission to dialysis, mean (SD), days 4.7 (8.3) 7.3 (20.9) 0.134
Ventilator 122 (82.4%) 361 (85.1%) 0.432
NPO 89 (60.1%) 248 (58.5%) 0.771
BUN, mean (SD), mg/dL 65.5 (36.2) 64.4 (37.8) 0.750
sCr, mean (SD), mg/dL 3.4 (2.0) 3.3 (1.8) 0.831
MAP, mean (SD), mmHg 80.1 (17.4) 81.2 (16.8) 0.498
CVP, mean (SD), cm 13.8 (6.0) 14.2 (5.6) 0.560
PaO2/FiO2, mean (SD), mmHg 320.6 (209.2) 279.6 (149.4) 0.011
Urine output, mean (SD), mL/24 hours 812.5 (840.5) 700.9 (755.1) 0.134
Anuria 29 (19.6%) 65 (15.5%) 0.250
Inotropic agents 99 (66.9%) 318 (75.2%) 0.053
Lactate, mean (SD), mmol/L 5.2 (4.5) 4.5 (2.2) 0.147
Sodium, mean (SD), mmol/L 139.8 (8.1) 139.6 (7.7) 0.721
Potassium, mean (SD), mmol/L 4.25 (0.86) 4.2 (0.8) 0.906
Disease severity score
APACHE II at ICU admission 11.4 (5.9) 11.2 (6.0) 0.688
APACHE II at initial dialysis 12.9 (5.5) 12.4 (6.2) 0.380
SOFA at ICU admission 9.0 (3.7) 8.1 (3.4) 0.006
SOFA at initial dialysis 10.9 (3.9) 11.2 (3.6) 0.369
SAPS at ICU admission 111.3 (14.3) 107.9 (13.4) 0.010
SAPS at initial dialysis 116.7 (13.4) 114.4 (13.6) 0.081
RIFLE at initial dialysis:
Risk 38 (25.7%) 113 (26.7%) 0.540
Injury 28 (18.9%) 74 (17.5%)
Failure 82 (55.4%) 237 (55.9%)
Dialysis modality at initial dialysis
IHD 34 (23.0%) 82 (19.3%) 0.540
SLED 11 (7.4%) 27 (6.4%)
CVVH 103 (69.6%) 315 (74.3%)
NOTE. Data are no. (%) of patients, unless otherwise indicated.
1Data correspond to the worst value in the 24 hours preceding the time point.
Abbreviations: APACHE II, acute physiology and chronic health evaluation;
BUN, blood urea nitrogen; CVP, central venous pressure; CVVH, continuous
venovenous hemofiltration; ICU, intensive care unit; IHD, intermittent
hemodialysis; MAP, mean arterial pressure; NPO, nil per os; RIFLE, risk of renal
failure, injury to kidney, failure of kidney function, loss of kidney function and
end-stage renal failure; SAPS, simplified acute physiological score; SD, standard
deviation; SOFA, Sequential Organ Failure Assessment; sCr, serum creatinine;
SLED, sustained low-efficiency dialysis.
IDefined as 3-day predialysis diuretic use.
doi:10.1371/journal.pone.0030836.t002
Table 1. Comparison of demographic of the nondiuretic and
diuretic groups.
Nondiuretic Diuretic p
(n=148) (n=424)
Male gender 103 (69.6%) 278 (65.6%) 0.418
Age, mean (SD), years 59.8 (18.2) 61.2 (16.1) 0.386
BMI, mean (SD), Kg/M
2 23.6 (4.1) 23.5 (3.8) 0.780
Elective operation 48 (32.4%) 170 (40.1%) 0.115
IABP 28 (18.9%) 79 (18.3%) 0.999
ECMO 40 (27.0%) 87 (20.5%) 0.108
CPR 30 (20.3%) 64 (15.1%) 0.156
Comorbid diseases
Diabetes mellitus 37 (25.0%) 141 (33.3%) 0.064
Hypertension 62 (41.9%) 188 (44.3%) 0.631
CHF 5 (3.4%) 17 (4.0%) 0.999
Cirrhosis 17 (11.5%) 47 (11.1%) 0.880
CKD 87 (58.8%) 234 (55.2%) 0.501
Sepsis 35 (23.6%) 87 (20.6% ) 0.485
Systemic organ failure
Central nervous system 28 (18.9%) 87 (20.5%) 0.722
Respiratory 27 (18.2%) 114 (26.9%) 0.036
Cardiac 42 (28.4%) 147 (34.7%) 0.187
Liver 29 (19.6%) 61 (14.4%) 0.149
Operation
Abdominal 50 (33.8%) 129 (30.5%) 0.696
Cardiovascular 76 (51.4%) 207 (48.9%)
Chest 14 (9.5%) 54 (12.8%)
Neurology 4 (2.7%) 22 (5.2%)
Urology 3 (2.0%) 8 (1.9%)
Orthopedic 1 (0.7%) 3 (0.7%)
NOTE. Data are no. (%) of patients, unless otherwise indicated.
Abbreviations: BMI, body mass index; CHF, congestive heart failure; CPR,
cardiopulmonary resuscitation; CKD, chronic kidney disease; ECMO,
extracorporeal membrane oxygenation; IABP, intraaortic balloon pump; SD,
standard deviation.
1Data correspond to the worst value in the 24 hours preceding the time point.
doi:10.1371/journal.pone.0030836.t001
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however, higher varying accumulated doses during the dialysis
period were associated with higher mortality. The total dose of
diuretics required to achieve the treatment goal might reflect the
severity of renal impairment and patients’ underlying clinical
status. Accumulated diuretic dose was significantly associated with
hypotension and mortality in a dose dependent manner.
Compared with patients who were not taking diuretics, those
taking diuretics had significant hypotension. (Table S2). This study
produced a novel finding that patients taking diuretics had lower
blood pressure in a dose-response manner, leading to a poor
prognosis throughout the duration of RRT [19]. Nevertheless, the
intensive high dose diuretic therapy should be tailored on the basis
of a close assessment of baseline hemodynamic data and
hemodynamic response to the medications, in addition to the
careful diuretic dose titration and cautious evaluation of risk/
benefit ratio [20].
Moreover, patients using diuretics during dialysis periods
showed borderline increasing daily urine output (p=0.075). ICU
care providers may underestimate the severity of renal injury when
urine output is sustained [13]. Our study has shown that loop
diuretics have negative effects on the natural history of AKI, apart
from a mild increase in urine output in the postsurgical critically ill
group. Fluid overload was independently associated with mortality
in patients with AKI [21]. However, the daily urine output and
body weight in our study were not associated with diuretic dose or
mortality in our cohort of dialysis patients. Fluid overload, in terms
of oliguria and increased body weight, led to more intense dialysis,
according to clinical adjustments made during the dialysis period
(Table S1). Large doses of furosemide activate the renin-
Table 3. Comparison of demographic of the postdialysis 30-
day survival and mortality patients.
Survival Mortality p
(n=289) (n=283)
Male gender 192 (66.4%) 189 (66.8%) 0.930
Age, mean (SD), years 59.7 (17.1) 62.0 (16.1) 0.100
BMI, mean (SD), Kg/M2 23.7 (3.7) 23.4 (4.1) 0.403
Elective operation 118 (40.8%) 100 (35.3%) 0.169
CPR 39 (13.5%) 55 (19.6%) 0.056
Diuretic use 213 (74%) 205(72.4%) 0.376
Comorbid diseases
Hypertension 131 (45.3%) 119 (42.0%) 0.449
DM 96 (32.9%) 82 (29.3%) 0.367
Cirrhosis 29 (10.0%) 35 (12.4%) 0.427
CKD 175 (60.6%) 146 (51.6%) 0.035
CHF 11 (3.8%) 11 (3.9%) 0.999
Sepsis 41 (14.2%) 81 (28.6) ,0.001
Systemic organ failure
Central nervous system 36 (12.5%) 79 (27.9%) ,0.001
Respiratory 50 (17.3%) 91 (32.2%) ,0.001
Cardiac 82 (28.4%) 107 (37.8%) 0.021
Liver 30 (10.4%) 60 (21.2%) 0.001
Operation
Abdominal 86 (29.6%) 93 (33.2%) 0.045
Cardiovascular 153 (52.6%) 130 (46.4%)
Chest 25 (8.6%) 43 (15.4%)
Neurology 16 (5.5%) 10 (3.6%)
Urology 8 (2.7%) 3 (1.1%)
Orthopedic 3 (1.0%) 1 (0.4%)
NOTE. Data are number (%) of patients, unless otherwise indicated.
Abbreviation: BMI, body mass index; CPR, cardiopulmonary resuscitation;
CKD, chronic kidney disease; CHF, congestive heart failure; DM, diabetics
mellitus; SD, standard deviation.
doi:10.1371/journal.pone.0030836.t003
Table 4. Comparison of predialysis characteristics of the
postdialysis 30-day survival and mortality patients.
Survival Mortality p
(n=289) (n=283)
Indication for acute dialysis
Azotemia 79 (27.3%) 86 (30.4%) 0.460
Fluid overload 31 (10.7%) 60 (21.2%) ,0.001
Hyperkalemia 21 (7.3%) 22 (7.8%) 0.875
Oliguria 143 (49.5%) 152 (53.7%) 0.317
Severe acidosis 7 (2.4%) 14 (4.9%) 0.123
At dialysis initiation
1
IABP 37 (12.8%) 70 (24.8%) ,0.001
ECMO 47 (16.3%) 80 (28.3%) 0.001
Diuretic use
I 216 (74.7%) 208 (73.5%) 0.775
Ventilator 230 (79.6%) 253 (89.4%) 0.001
NPO 156 (54.0%) 181 (64.0%) 0.017
Serum creatinine, mean (SD), mg/dL 3.6 (1.9) 3.1 (1.9) 0.002
Blood urea nitrogen, mean (SD), mg/dL 64.4 (33.4) 65.0 (41.1) 0.841
Potassium, mean (SD), mmol/L 4.3 (0.8) 4.2 (0.8) 0.483
MAP, mean (SD), mmHg 84.5 (17.1) 77.3 (15.9) ,0.001
APACHE II, mean (SD) 10.7 (5.3) 14.4 (6.1) ,0.001
SOFA, mean (SD) 9.9 (3.2) 12.5 (3.6) ,0.001
SAPS, mean (SD) 110.5 (11.9) 119.7 (13.4) ,0.001
PaO2/FiO2, mean (SD), mmHg 306.2 (161.6) 274.1 (172.7) 0.023
RIFLE
Risk 79 (27.3%) 72 (25.4%) 0.848
Injury 52 (18.0%) 5 (17.7%)
Failure 158 (54.7%) 161 (56.9%)
Lactate, mean (SD), mmol/L 3.9 (4.1) 5.5 (5.1) 0.001
CVP, mean (SD), mmHg 13.6 (5.5) 14.5 (5.8) 0.053
Urine output, mean (SD), mL/24 hours 768 (792) 692 (766) 0.246
Dialysis modality at dialysis
initiation
IHD 78 (27.0%) 38 (13.4%) ,0.001
SLED 22 (7.6%) 16 (5.7%)
CVVH 189 (65.4%) 229 (80.9%)
NOTE. Data are number (%) of patients, unless otherwise indicated.
Abbreviation: APACHE II, acute physiology and chronic health evaluation;
CVP, central venous pressure; CVVH, continuous venovenous hemofiltration;
ECMO, extracorporeal membrane oxygenation; IABP, intraaortic balloon pump;
MAP, mean arterail pressure; NPO, nil per os; RIFLE, risk of renal failure, injury to
kidney, failure of kidney function, loss of kidney function, and end-stage renal
failure (RIFLE) classification; SD, standard deviation; SOFA, Sequential Organ
Failure Assessment; SAPS, simplified acute physiological score; IHD, intermittent
hemodialysis; sCr, serum creatinine, SLED, sustained low-efficiency dialysis.
1Data correspond to the worst value in the 24 hours preceding the time point.
IDefined as 3-day predialysis diuretic use.
doi:10.1371/journal.pone.0030836.t004
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left ventricular pump deterioration [22]. Actually, there is a risk
that a tubular or glomerular injury can be generated and that a
preexisting renal dysfunction can be aggravated, especially when
excessive doses of loop diuretics are being erroneously adminis-
tered [20]. Hence, caution should be taken when furosemide is
administered to postsurgical patients undergoing dialysis.
In our report, daily dialysis with IHD demonstrated a survival
benefit as compared with no dialysis; however, daily dialysis with
CVVH was marginally associated with poor prognosis (Table 6).
Although the results showed that CVVH had a survival disadvan-
tage, this could reflect residual confounding by illness severity
because we used CVVH in more severely, acutely ill patients.
Moreover, lower dialysis intensity was related to higher accumu-
lated diuretic use, a common observation in clinical practice. Initial
clinical trial data on the use of UF have demonstrated promising
cardiac outcomes with regard to fluid removal and symptom relief,
without worsening renal function [23]. The addition of a solute
clearance component by dialysis may provide additional benefits for
these patients with varying degrees of renal impairment [24].
Moreover, our study analysis has several notable strengths.
Firstly, the relationship between lower daily blood pressure and
higher diuretic dose throughout the duration of RRT was a robust
finding resistant to the influence of most variables. Therefore,
future randomized trial studies that stratify patients according to
diuretic use should stress the relationship between blood pressure
and diuretic dose. Secondly, we focused on diuretic use in
heterogeneous, multicenter postsurgical patients using a compre-
hensive statistical approach and a large prospective database of
patients with acute dialysis; therefore, our results could be
extrapolated to other critical care situations because the current
use of diuretics depends on clinical judgment without consensus.
Thirdly, the propensity score for diuretic use and the need for
dialysis were adjusted for time variable models, allowing us to
incorporate changes in disease progression after dialysis for AKI
and potentially providing useful prognostic information regarding
important complications in intensive care units. However, patient
heterogeneity could lead to confounding, and most of our patients
were cardiovascular in nature. Future observational studies and
clinical trials with regard to AKI should attempt to understand the
long-term effects of diuretic-associated episodes.
Our study has shown that higher loop diuretic doses are
associated with significant grave effects on critical patients who
require acute RRT after major surgery. Higher diuretic doses
were associated with hypotensive episodes after initializing dialysis,
lower daily oxygen saturation and lactate level or poor kidney
function parameters and was associated with higher patient
mortality. Forced diuresis as an indicator of adequate renal
function has less scientific rationale under such circumstances.
Caution should be taken when loop diuretics is administered to
postsurgical patients during acute dialysis. Future larger random-
ized clinical trials are required to confirm and validate the adverse
effect of diuretic use in acute dialysis patients.
Methods
Study cohort
This study was based on a clinical cohort study of the renal
failure patients in the database of the National Taiwan University
Hospital Study Group for Acute Renal Failure (NSARF). The
Institutional Review Board of the National Taiwan University
Hospital approved the study (No. 31MD03) and waived the need
of informed consent because there was neither breach of privacy
nor interference with clinical decisions related to patient care.
This non-concurrent prospective cohort for quality assurance has
been maintained since January 2002 in one medical center
(National Taiwan University Hospital, Taipei, Taiwan) and its
three branch hospitals in different cities [12,25,26,27,28]. A total of
16,740 adult patients (age.18 years) were admitted to the SICU,
and 852 patients received renal replacement therapy (RRT) during
their hospitalization before January 2008. Patients with chronic
dialysis (n=217) and without operations (n=63) were excluded
(Fig. 1). A total of 572 patients were included in this study. Surgical
procedures were considered major if the length of the ICU stay for
patients in a given diagnosis-related group exceeded two days [29].
Clinical evaluation
Demographics, clinical characteristics at ICU admission and
predialysis were assessed. Clinical evaluations included medical
history, physical examination, and identification of comorbid
diseases. Medical history included the presence of diabetes mellitus
(DM, defined as having been treated with oral hypoglycemic
agents or insulin), peripheral vascular disease (defined as having
had a previous vascular procedure, a history of claudication, or the
presence of femoral bruits), hypertension (defined as having taken
antihypertensive drugs or having systolic and diastolic blood
pressures .145/95 mmHg at the time of hospitalization), and
chronic kidney disease (CKD, defined as estimated glomerular
filtration rate (eGFR),60 mL/min/1.73 m
2 noted at ICU
admission) [30]. Oliguria was defined as a urine volume,100 mL
in 8 hours [31]. Sepsis was defined as the presence of both
infection and systemic inflammatory response syndrome (SIRS) as
in previous reports [32,33]. A diet of 1.0–1.2 g protein/kg/day
was prescribed for these patients.
Critical scoring systems, hemodynamic data, biochemistry data,
and urine output were assessed after SICU admission and followed
prospectively from the day that hemodialysis began. Physiological
calculations were performed using the worst physiologic values
Table 5. Multiple logistic regression model for estimating the
propensity score of diuretic exposure at acute dialysis
initiation.
Odds 95%
Covariate Estimate ratio confidence limits p
Diabetes (yes) 0.522 1.685 1.032 2.751 0.037
CPR (yes) 20.522 0.593 0.335 1.051 0.074
Predialysis urine output
(mL/day)
20.001 0.999 0.999 1.000 0.001
Congestive heart failure (yes) 0.531 1.700 1.000 2.888 0.050
Creatinine at ICU admission
(mg/dL)
20.134 0.874 0.774 0.988 0.031
Lactate (mmol/L) 20.049 0.952 0.910 0.996 0.033
Predialysis PaO2/FiO2 (mmHg) 20.001 0.999 0.998 1.000 0.039
Abbreviations: CPR, cardiopulmonary resuscitation; OR, odds ratio; ICU,
intensive care unit.
Adjusted for gender, age, body mass index, elective operation,
cardiopulmonary resuscitation, extracorporeal membrane oxygenation,
cardiopulmonary resuscitation, ventilator use, days from hospital admission to
dialysis, NPO status, total parenteral nutrition, blood pressure, BUN, creatinine,
lactate, urine output, body weight, anuria, inotropic equivalent, lactate, sodium,
potassium, APACHE II at initializing dialysis, diabetes mellitus, hypertension,
congestive heart failure, cirrhosis, chronic kidney disease, systemic organ failure
(central nervous system, respiratory, cardiac, liver), operation categories
(abdominal, cardiovascular, chest, neurology, urology, orthopedic), and
indication for dialysis (azotemia, fluid overload, hyperkalemia, oliguria, acidosis).
doi:10.1371/journal.pone.0030836.t005
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biochemical data [34], we recorded patients’ clinical parameters
such as blood pressure, BUN, lactate, creatinine, urine output,
body weight and dialysis intensity daily at 8:00 a.m.
The 30-day mortality, defined as death within 30 days after acute
dialysis initiation, was the primary outcome variable. Vital signs,
hemodynamic data, and laboratory data between groups were
examined atthetimeofdialysisinitiation. Anuria was definedas urine
output of less than 100 mL/day. Diuretics were prescribed according
to the clinical judgment in terms of patients’ urine output and fluid
status. Therefore the dose of diuretic was collected retrospectively.
Diuretics were held if daily urine output is still less than 100cc after a
single dose challenge of furosemide. The daily diuretic dose of each
patient was recorded and calculated after hemodialysis was initiated.
Only two types of loop diuretic, bumetanide and furosemide, were
used in our unit. For the calculation, 1 mg of bumetanide was
considered to be equivalent to 40 mg of furosemide [13,26]. Because
the frequency and dose of diuretic varied during dialysis, the time-
varying 3-day accumulative diuretic dose was integrated to analyze
the effect of diuretic use and dosage on patient mortality [11]. The
time-varying 3-day accumulative diuretic dose was recorded as the
total dose of diuretic received within the 3-day prior to dialysis and
every 3-days after dialysis initiation.
Renal replacement therapy (RRT)
The indication for RRT has been previously reported [25,26,27],
namely, (1) azotemia (BUN.80 mg/dL) with uremic symptoms
(165 patients); (2) fluid overload with a central venous pressure
.12 mm Hg or pulmonary edema with a PaO2/FiO2,300 (90
patients);(3)hyperkalemia (serumK
+.5.5 mmol/L)despite medical
treatment (43 patients); (4) oliguria (urine amount,100 mL/8 h)
with or without diuretic use (295 patients); and (5) acidosis (pH,7.2
in arterial blood gas) (21 patients).
The RRT modality was chosen according to patient hemody-
namics, as previously reported [12,25]. Continuous venovenous
hemofiltration (CVVH) was used if an inotropic equivalent (IE)
dose [35] of more than 15 points was required to keep systolic
blood pressure (SBP) above 120 mmHg when RRT was initiated;
or if SBP,120 mmHg despite inotropic agents. CVVH was
performed with high-flux filters (Hemofilter, PAN-10, Asahi Kasei
Table 6. Cox’s model with time-dependent covariates showing the estimated hazard ratios (HRs) for 30-day mortality in the
postsurgical acute dialysis patients
1.
Parameter Adjusted 95%
Covariate estimate HR confidence interval p
Age (years) 0.015 1.015 1.018–1.023 ,0.001
At dialysis initiation
IABP 0.316 1.372 1.018–1.873 0.044
APACHE II 0.046 1.047 1.037–1.078 ,0.001
Systemic organ failure
Sepsis 0.432 1.541 1.183–2.015 0.001
Liver 0.699 2.011 1.476–2.763 ,0.001
Indication for acute dialysis
Azotemia 0.273 1.314 1.025–1.705 0.038
Time-varying hazard (daily)
PaO2/FiO2 (mmHg) 20.002 0.998 1.007–1.009 ,0.001
Lactate (mmol/L) 0.171 1.186 1.144–1.236 ,0.001
Time-varying three day accumulative 0.371 1.449 1.060–1.981 0.021
diuretic dose (g/3day)
Varying daily dialysis modality
Daily IHD vs. No dialysis 20.420 0.657 0.453–0.960 0.030
Daily CVVH vs. No dialysis 0.222 1.248 0.934–1.684 0.141
Daily SLED vs. No dialysis 20.430 0.651 0.397–1.106 0.107
Inotropic equivalents at ICU admissionI 20.002 0.998 0.990–1.001 0.107
Inotropic equivalent at DialysisI 0.003 1.003 1.000–1.010 0.357
Propensity score
adjusted diuretic use 20.866 0.421 0.153–1.159 0.092
NOTE. Data are number (%) of patients, unless otherwise indicated.
Abbreviations: APACHE, acute physiology and chronic health evaluation; BUN, blood urea nitrogen; CVVH, continuous venovenous hemofiltration; IABP, intraaortic
balloon pump; MBP, mean blood pressure; IHD, intermittent hemodialysis; TPN, total parenteral nutrition; SLED, sustained low-efficiency dialysis.
1Adjusted for gender, age, body mass index, elective operation, cardiopulmonary resuscitation, extracorporeal membrane oxygenation, cardiopulmonary resuscitation,
ventilator use, days from hospital admission to dialysis, NPO status, total parenteral nutrition, time-varying variables (blood pressure, BUN, creatinine, lactate, urine
output, body weight, time-varying three day accumulative diuretic dose, daily dialysis modality and dialysis intensity), anuria, inotropic equivalent, lactate, sodium,
potassium, APACHE II at initial dialysis, diabetes mellitus, hypertension, congestive heart failure, cirrhosis, chronic kidney disease, sepsis, shock, systemic organ failure
(central nervous system, respiratory, cardiac, liver), operation categories (abdominal, cardiovascular, chest, neurology, urology, orthopedic), and indication for dialysis
(azotemia, fluid overload, hyperkalemia, oliguria, acidosis).
IInotropic equivalent=[(dopamine+dobutamine)+(milrinone615)+[(epinephrine+norepinephrine+isoproterenol)6100] in mcg/kg/min [35,40].
doi:10.1371/journal.pone.0030836.t006
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Switzerland) and a hemofiltration flow of 35 mL/kg/hour with a
blood flow of 200 mL/min. Replacement fluid was bicarbonate-
buffered and was administered predilutionally at a dynamically
adjusted volume to achieve the desired fluid therapy goals.
Sustained low efficiency dialysis (SLED) was operated by the
same group of technicians, nephrologists, and intensive care
physicians as CVVH using a previously reported standard protocol
[12]. SLED was delivered for 8 hours daily, from 9:00 a.m. to 5:00
p.m., using conventional HD machines (Fresenius 4008B, Fresenius
Medical Care AG, Bad Homburg, Germany) and a Fresenius F8
dialyzer (Polysulfone, Fresenius Medical Care, Taipei, Taiwan).
Blood flow was 200 mL/min, and the dialysate flow was 300 mL/
min. Patients wereeligible for SLED if they met one of the following
two criteria [12]: (1) severe fluid overload (defined as an estimated
ultrafiltration .2.5 L during a single dialysis session) and a central
venous pressure level .15 mmHg or pulmonary edema with
PaO2/FiO2,200 mmHg despite diuretic treatment, modified from
a SOFA respiratory score of 3 or 4 [36], or (2) moderately unstable
hemodynamics (defined as SBP 120–140 mmHg with inotropic
equivalent (IE) score 5–15 [35]). Otherwise, intermittent hemodi-
alysis was used. Typically, most patients were treated with more
than one RRT modalities during an AKI episode. Because of the
use of different RRT modalities (continuous and intermittent), the
dialysis intensity was defined as the number of dialysis days divided
by the dialysis period and determined by consensus among the
attending intensivists and nephrologists.
Disease severity
Organ failure was classified according to the following findings
[25,26]: respiratory failure, with ventilator support; coagulopathy,
platelet count #50610
3/mm
3; central nervous system failure,
Glasgow coma score #9; cardiac failure, signs of low cardiac output
with a central venous pressure .12 mm Hg and the administration
of an IE.5 points;and liver dysfunction, total bilirubin $2.0 mg/dL
with INR.1.4. Sepsis was defined as the persistence or progression of
signs and symptoms of the systemic inflammatory response syndrome
with a documented or presumed persistence of infection [32].
Statistical analysis
Statistical analyses were performed using SAS software, Version
9.1.3 (SAS Institute Inc., Cary, NC, U.S.A.) and R software, Version
2.8.1 (Free Software Foundation, Inc., Boston, MA, U.S.A.). A two-
sided p value#0.05 was considered statistically significant. The
continuousvariablesweresummarizedasmean6standard deviation
(SD) unless otherwise indicated, whereas the categorical variables
were presented as proportions. A two-sample student’s t-test was used
to test the difference in the means of continuous variables between
groups, and the chi-square test or Fisher’s exact test was used to
analyze the associations between two categorical variables.
Moreover, because diuretic use was randomly assigned, the
potential selection bias was controlled by applying propensity score
analysis (PSA) [37]. To estimate each patient’s propensity score for
diuretic use, we fitted a separate multivariable logistic regression
model with the factors predicting diuretic use [6] (further seen at
File S1).
In the multivariate analysis, Cox’s regression model with time-
dependent covariates [11] was used to test the associations
between the prognostic factors and the hazard rate of mortality
within 30 days. Patients were censored at the time of withdrawal
from RRT or at the end of the 30-day observation period. The
baseline values for mean arterial pressure, O2 index, IE, lactate
level, BUN, creatinine, and urine output when dialysis began and
the time-varying values of their repeated measurements during the
30 days after RRT were also analyzed. Besides, the frequency and
modality of RRT were also added as independent covariates to
evaluate the effect of RRT intensity.
Additionally, to visualize the potential nonlinear effects of
continuous covariates, such as the 3-day cumulative diuretic dose,
a generalized additive models (GAM)-type approach was applied
Figure 3. Accumulated diuretics dose predicts post dialysis mortality. Time-varying three-day accumulative diuretic dose (equivalent to
furosemide dose) predicts 30 days mortality after undergoing acute dialysis. The smoothed plot of a generalized additive model included all
demographic variables in the time-varying analyses, plus comorbid states (p,0.001).
doi:10.1371/journal.pone.0030836.g003
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regression and spline smoothing techniques [38].
Finally, to examine the effect of diuretic use on various time-
dependent variables, marginal linear regression models were fitted
to these repeatedly measured responses using the generalized
estimating equations (GEE) method [39] (further seen at File S1).
The estimated propensity score of diuretic exposure and the need
for dialysis was also added into the GEE marginal linear regression
models as a covariate to adjust for the selection bias from diuretic
use [6].
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